A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity

Active, not recruiting

Phase 3 Results N/A

Summary of Purpose

Botulinum toxin A (GSK1358820) is a sterile, purified type A botulinum neurotoxin complex. In Japan, 240 units of botulinum toxin A are approved as a maximum dose per administration for upper limb spasticity. This study is planned to evaluate the effectiveness and safety of 400 units of botulinum toxin A which can help to increase the maximum dose per administration to 400 units from 240 units as the treatment...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 5 April 2018.

2 Aug 2017 23 Aug 2017 28 Jan 2019 28 Feb 2019 1 Apr 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

Not available